FDA Brief

Warning letters Drugs

FDA warning letter to

Best Chinese Medicines LLC

High riskIssued Oct 23Posted Oct 27Center for Drug Evaluation and Research (CDER)

FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

What happened

FDA reviewed the company’s website, https://bestchinesemedicines.com, in September 2026. FDA found that the labeling for five products made claims to treat diseases and conditions, including tumors, high blood pressure, arrhythmias, Covid-19 symptoms, and arthritis, so FDA treated the products as drugs. FDA said no approved applications are in effect for them, making them unapproved new drugs.

What FDA found

  1. FDA says Dissolve Mass Stasis Breaker is an unapproved new drug because its webpage says it helps dissipate nodules, palpable masses, and tumors, and no FDA-approved application is in effect for it.

    FD&C Act sections 301(d), 201(g)(1), 201(p), 505(a); 21 U.S.C. 331(d), 321(g)(1), 321(p), 355(a)
  2. FDA says Gynostemma Leaf (Penta) Jiao Gu Lan is an unapproved new drug because its webpage and blog say it lowers LDL cholesterol, raises HDL cholesterol, controls blood pressure, and restores healthy blood pressure, and no FDA-approved application is in effect for it.

    FD&C Act sections 301(d), 201(g)(1), 201(p), 505(a); 21 U.S.C. 331(d), 321(g)(1), 321(p), 355(a)
  3. FDA says Wenxin Keli is an unapproved new drug because its webpage says it is for arrhythmias, palpitations, shortness of breath, chest pain, ventricular contractions, atrial premature beats, and other cardiovascular disease, and no FDA-approved application is in effect for it.

    FD&C Act sections 301(d), 201(g)(1), 201(p), 505(a); 21 U.S.C. 331(d), 321(g)(1), 321(p), 355(a)
  4. FDA says Lianhua Qingwen Capsules is an unapproved new drug because its webpage says it is a popular treatment for symptoms related to Covid-19 and is kept on hand during cold and flu season and periods of increased respiratory concerns, and no FDA-approved application is in effect for it.

    FD&C Act sections 301(d), 201(g)(1), 201(p), 505(a); 21 U.S.C. 331(d), 321(g)(1), 321(p), 355(a)
  5. FDA says Duhuo Jisheng Wan is an unapproved new drug because its webpage says it is for lower back pain, joint pain, rheumatoid arthritis, diabetic neuropathy, and osteoarthritis, and no FDA-approved application is in effect for it.

    FD&C Act sections 301(d), 201(g)(1), 201(p), 505(a); 21 U.S.C. 331(d), 321(g)(1), 321(p), 355(a)

What FDA wants

FDA tells the company to send a written response within 15 business days to FDAAdvisory@fda.hhs.gov with the corrective steps taken, steps to prevent recurrence, and supporting documents, using reference number 738556. FDA also says to promptly address the violations.

Who should pay attention

  • online sellers of herbal products
  • retailers or marketplaces listing Chinese medicine formulas
  • consumers who rely on disease-treatment claims on product websites

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk